Dose reduction of docetaxel avoids the usage of pegfilgrastim in docetaxel plus ramucirumab therapy for recurrent nonsmall cell lung cancer
Abstract Background Pegfilgrastim is recommended in docetaxel plus ramucirumab (DTX + RAM) therapy for recurrent nonsmall cell lung cancer (NSCLC) because of the associated frequency of febrile neutropenia (FN). However, the FN occurs less frequently when the dose of DTX is reduced because of other...
| Автори: | , , , , , , , , |
|---|---|
| Формат: | Стаття |
| Мова: | English |
| Опубліковано: |
Wiley
2023-04-01
|
| Серія: | Cancer Reports |
| Предмети: | |
| Онлайн доступ: | https://doi.org/10.1002/cnr2.1793 |